Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- Cantox to Host Educational Seminar Regarding Section 912: Potential Threat to Food Innovation
Cantox Health Sciences International will be hosting a seminar regarding Section 912, part of a law that includes prohibition that represents a shift in the dividing line between foods and drugs, and threatens to present significant hurdles for anyone involved in product development.
- FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission has announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some complaints allege that the companies also falsely touted clinical or scientific proof for their products.
- FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission has announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some complaints allege that the companies also falsely touted clinical or scientific proof for their products.
- FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission has announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some complaints allege that the companies also falsely touted clinical or scientific proof for their products.
- FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission has announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some complaints allege that the companies also falsely touted clinical or scientific proof for their products.
- FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission has announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some complaints allege that the companies also falsely touted clinical or scientific proof for their products.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Workshop Clarifies Health Claims Regulations
Health claims regulation across Asia and the European Union will come under the spotlight at an upcoming workshop hosted by international food and nutrition policy consultancy EAS. ‘The Practical Implications of Claims Regulations and key steps to successfully accessing markets in Asia & Europe’, will guide companies through the current rules for health claims in key Asian markets and Europe. It is scheduled for November 18, 2008.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products. Cognis is one of the first German companies to receive this certificate.
Consumers all over the world expect food to be of high quality and safe. ISO 22000:2005 is a globally harmonized and recognized standard for management systems to ensure food safety. Cognis has established such a system at its production site in Illertissen, Bavaria. The certificate now issued confirms that all products which are manufactured, filled, and globally marketed meet the quality and safety requirements of the standard. These products include Vegapure® (sterol esters), Tonalin® (conjugated linoleic acid), Omevital® (omega-3 fish oils), Delios® (MCT oils) and special triglycerides for use in the segments functional food (dairy products, margarine, and beverages) and dietary supplements.
Gerhard Lobmaier, Vice President Nutrition & Health Europe, explains: “Our new management system for food safety complements our existing systems for quality and environmental management perfectly. For our customers all over the world, this successful certification is a further proof that our products meet the highest quality standards.”
DQS confirmed that Cognis has implemented the requirements of ISO 22000:2005 on an above-average level. “To meet these standards Cognis has appointed a food safety team combining competencies in quality management, microbiology, food technology, food law, chemistry, and engineering,” says Andreas Heidbreder, Site Manager Cognis Illertissen. The team is responsible for monitoring processes and products and for ensuring that all products are manufactured in observance of the safety standards and specifications. Additionally, a preventive HACCP system (Hazard Analysis of Critical Control Points) was implemented to analyze and eliminate possible causes of health risks from the complete production to the point of transportation.
Cognis Nutrition & Health is the company’s strategic business unit specializing in food ingredients. It maintains a production site in Illertissen, Bavaria, for emulsifiers, plant sterol esters, and conjugated linoleic acid (CLA). The international Competence Center Nutrition & Health is also located in Illertissen. In 2007, the esterification plants were expanded with a ten million euro investment.
About Cognis
Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 7,600 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2007, Cognis recorded sales of about 3.52 billion euros and an Adjusted EBITDA (operating result) of 410 million euros. |